Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTL NASDAQ:DFTX NASDAQ:PGNY NASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$21.38-1.0%$22.59$14.59▼$44.28$648.30M1.04403,457 shs63,235 shsDFTXDefinium Therapeutics$24.17-1.7%$21.73$6.34▼$26.25$2.41B2.371.83 million shs1.10 million shsPGNYProgyny$25.66+0.7%$20.42$16.10▼$28.75$2.01B1.031.55 million shs441,701 shsVRDNViridian Therapeutics$16.05-3.1%$16.86$13.18▼$34.29$1.66B0.92.25 million shs435,126 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences+5.93%-2.31%-12.20%-20.35%+26.91%DFTXDefinium Therapeutics+4.20%+4.68%+9.73%+39.18%+221.31%PGNYProgyny+1.96%-0.82%+34.25%+39.16%+19.62%VRDNViridian Therapeutics+1.35%-5.04%-11.73%-41.53%+17.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$21.38-1.0%$22.59$14.59▼$44.28$648.30M1.04403,457 shs63,235 shsDFTXDefinium Therapeutics$24.17-1.7%$21.73$6.34▼$26.25$2.41B2.371.83 million shs1.10 million shsPGNYProgyny$25.66+0.7%$20.42$16.10▼$28.75$2.01B1.031.55 million shs441,701 shsVRDNViridian Therapeutics$16.05-3.1%$16.86$13.18▼$34.29$1.66B0.92.25 million shs435,126 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences+5.93%-2.31%-12.20%-20.35%+26.91%DFTXDefinium Therapeutics+4.20%+4.68%+9.73%+39.18%+221.31%PGNYProgyny+1.96%-0.82%+34.25%+39.16%+19.62%VRDNViridian Therapeutics+1.35%-5.04%-11.73%-41.53%+17.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 2.67Moderate Buy$42.83100.34% UpsideDFTXDefinium Therapeutics 3.00Buy$37.9257.49% UpsidePGNYProgyny 2.93Moderate Buy$29.6715.37% UpsideVRDNViridian Therapeutics 2.79Moderate Buy$36.14123.05% UpsideCurrent Analyst Ratings BreakdownLatest CSTL, DFTX, PGNY, and VRDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026PGNYProgyny Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $31.006/1/2026CSTLCastle Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026CSTLCastle Biosciences KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.005/26/2026CSTLCastle Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2026PGNYProgyny Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$19.00 ➝ $30.005/15/2026PGNYProgyny BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$23.00 ➝ $27.005/15/2026VRDNViridian Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.005/13/2026VRDNViridian Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$39.005/13/2026CSTLCastle Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.005/11/2026PGNYProgyny CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/11/2026PGNYProgyny Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $30.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$339.92M1.91$1.17 per share18.32$16.13 per share1.33DFTXDefinium TherapeuticsN/AN/AN/AN/A$3.36 per shareN/APGNYProgyny$1.29B1.56$0.76 per share33.94$5.99 per share4.29VRDNViridian Therapeutics$70.92M23.55N/AN/A$6.18 per share2.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences-$24.16M-$0.44N/AN/AN/A-3.78%-2.77%-2.30%8/3/2026 (Estimated)DFTXDefinium Therapeutics-$183.79M-$2.49N/AN/AN/AN/A-100.30%-69.22%N/APGNYProgyny$58.52M$0.7733.3819.481.335.23%13.34%9.03%8/6/2026 (Estimated)VRDNViridian Therapeutics-$342.60M-$3.32N/AN/AN/A-490.31%-80.19%-48.84%8/5/2026 (Estimated)Latest CSTL, DFTX, PGNY, and VRDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026DFTXDefinium Therapeutics-$0.4780-$0.71-$0.2320-$0.71N/AN/A5/7/2026Q1 2026PGNYProgyny$0.2560$0.50+$0.2440$0.29$326.47 million$328.50 million5/6/2026Q1 2026CSTLCastle Biosciences-$0.49-$0.49N/A-$0.49$79.23 million$84.23 million5/5/2026Q1 2026VRDNViridian Therapeutics-$1.06-$0.90+$0.16-$0.90$0.04 million$0.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/ADFTXDefinium TherapeuticsN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.026.756.53DFTXDefinium Therapeutics0.154.694.69PGNYProgynyN/A2.132.13VRDNViridian Therapeutics0.1015.1515.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%DFTXDefinium Therapeutics27.91%PGNYProgyny94.93%VRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences6.10%DFTXDefinium Therapeutics2.40%PGNYProgyny9.90%VRDNViridian Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54030.33 million28.48 millionOptionableDFTXDefinium Therapeutics4099.70 million97.31 millionOptionablePGNYProgyny31078.33 million70.58 millionOptionableVRDNViridian Therapeutics50103.08 million100.60 millionOptionableCSTL, DFTX, PGNY, and VRDN HeadlinesRecent News About These CompaniesViridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program2 hours ago | globenewswire.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 3 at 6:14 AM | americanbankingnews.comViridian Therapeutics Fully Repays Loan, Ends AgreementMay 28, 2026 | tipranks.comViridian Therapeutics secures WuXi deal for veligrotug manufacturingMay 26, 2026 | tipranks.comViridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350MMay 21, 2026 | finance.yahoo.comViridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel ProjectMay 19, 2026 | globenewswire.comViridian Therapeutics Announces Presentations at Multiple Medical Meetings in SeptemberMay 17, 2026 | businesswire.comThis Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionMay 17, 2026 | fool.comViridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special MeetingMay 14, 2026 | globenewswire.comInsider Buying: Viridian Therapeutics (NASDAQ:VRDN) Director Acquires 1,176,470 Shares of StockMay 14, 2026 | insidertrades.comViridian Therapeutics Raises $359 Million in OfferingsMay 13, 2026 | theglobeandmail.comVanguard Group Inc. Raises Holdings in Viridian Therapeutics, Inc. $VRDNMay 11, 2026 | marketbeat.comViridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - SlideshowMay 9, 2026 | seekingalpha.comViridian Therapeutics (NASDAQ:VRDN) Upgraded at Wall Street ZenMay 9, 2026 | marketbeat.comEarnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their EstimatesMay 8, 2026 | finance.yahoo.comWhy Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh FundraisingMay 8, 2026 | finance.yahoo.comQ2 EPS Forecast for Viridian Therapeutics Boosted by AnalystMay 8, 2026 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Sees Large Volume Increase - Time to Buy?May 7, 2026 | marketbeat.comViridian (VRDN) Climbs 33% on Looming Drug CommercializationMay 7, 2026 | finance.yahoo.comViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350 ...May 7, 2026 | finance.yahoo.comViridian Therapeutics prices upsized $350M concurrent stock and convertible notes offeringsMay 7, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSTL, DFTX, PGNY, and VRDN Company DescriptionsCastle Biosciences NASDAQ:CSTL$21.38 -0.22 (-1.02%) As of 12:51 PM Eastern This is a fair market value price provided by Massive. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Definium Therapeutics NASDAQ:DFTX$24.17 -0.42 (-1.71%) As of 12:34 PM EasternMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Progyny NASDAQ:PGNY$25.66 +0.18 (+0.69%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Viridian Therapeutics NASDAQ:VRDN$16.05 -0.52 (-3.14%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
